Published in Platelets on August 18, 2016
A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem (2002) 5.02
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev (2004) 4.41
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost (2007) 2.34
Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol (2002) 2.16
Cyclooxygenases: structural and functional insights. J Lipid Res (2008) 2.14
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A (2002) 1.39
Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet (1999) 1.16
Real-time PCR assay for detection and quantification of hepatitis B virus genotypes A to G. J Clin Microbiol (2006) 1.13
Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J (2006) 1.12
Lactadherin and clearance of platelet-derived microvesicles. Blood (2008) 1.07
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res (2013) 1.03
Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci (2013) 0.99
Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res (2014) 0.89
Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. Oncogene (2005) 0.83
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice. Thromb Haemost (2015) 0.80